<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34976">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689220</url>
  </required_header>
  <id_info>
    <org_study_id>SP-02L03</org_study_id>
    <nct_id>NCT01689220</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea</brief_title>
  <official_title>A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solasia Pharma K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synex Consulting Korea Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Solasia Pharma K.K.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy
      in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity and adverse events</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response (overall response)</measure>
    <time_frame>2 and 4 cycles</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profile</measure>
    <time_frame>0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and 5, and 0 hour on Day 2, 3, 4, 6, 8 and 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Area under curve, Tmax, t1/2, Clearance and Volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>SP-02L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-02L (darinaparsin for injection)</intervention_name>
    <description>Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle).  Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.</description>
    <arm_group_label>SP-02L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-02L (darinaparsin for injection)</intervention_name>
    <description>Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.</description>
    <arm_group_label>SP-02L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean patients aged â‰¥ 20 years of age at the day of obtaining the informed consent

          -  Patients with histologically confirmed diagnosis of the following:

               -  PTCL, not otherwise specified (PTCL-NOS)

               -  Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)

               -  Angioimmunoblastic T-cell Lymphoma (AITL)

          -  Have relapsed or refractory to at least one prior systemic chemotherapy for the above
             disease (currently requiring therapy)

          -  Have at least 1 evaluable lesion

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy of at least 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 26, 2013</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
